Search for a trial | Research with human participants

1 results

Phase 1/2, Open-label, Dose Escalation and Dose Expansion Study of TransCon TLR7/8 Agonist Alone or in Combination with Pembrolizumab in Participants with Locally Advanced or Metastatic Solid Tumor Malignancies

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2024-517150-10-00 check the CTIS register for the current data. Primary:- To evaluate the safety and tolerability, and define the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of…